{"schema_version":"secwatch.filing_event.v1","accession":"0000711404-22-000010","form_type":"8-K","ticker":"COO","cik":"0000711404","company_name":"COOPER COMPANIES, INC.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.502229+00:00","generated_at":"2026-06-27T02:11:00.958125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CooperCompanies Q1 revenue up 16% to $787M; non-GAAP EPS $3.24","bullets":["Revenue $787.2M (+16% YoY); CooperVision +11% to $561.5M, CooperSurgical +30% to $225.7M.","GAAP diluted EPS $1.91 (vs $42.31 prior year due to deferred tax benefit); non-GAAP diluted EPS $3.24 (+2%).","Net debt $2,981.5M after Generate Life Sciences acquisition; adjusted leverage 2.71x.","FY2022 guidance: revenue $3,261-$3,329M; non-GAAP EPS $13.70-$14.20."],"urls":{"canonical":"https://secwatch.observer/filing/0000711404-22-000010","json":"https://secwatch.observer/filing/0000711404-22-000010.json","markdown":"https://secwatch.observer/filing/0000711404-22-000010.md","text":"https://secwatch.observer/filing/0000711404-22-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/0000711404-22-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/coo-20220303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:11:00.958125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}